CLOs on the Move


 
  • Number of Employees:
  • Annual Revenue:

  • ,

Executives

Name Title Contact Details

Similar Companies

SAENZ-GARCIA LAW, PLLC

We provide tailored, compassionate, and professional immigration legal services to individuals and families. We are a dedicated ally on the journey to a brighter future, we go beyond immigration law.

Weekes Forest Products, Inc

Weekes Forest Products, Inc. (WEEKES) is a St. Paul, Minnesota based wholesaler and distributor of wood products and building materials. Founded in 1978, WEEKES has grown to become one of the most successful independently-owned distributors in the United States. Financial Data. WEEKES has earned a reputation as a highly entrepreneurial, sales-driven company with a history of financial success. WEEKES has 8 regional locations. Seven of these enterprises were the result of acquisitions WEEKES has completed since 1986. In the United States, many local and regional distribution companies could add to WEEKES​ growth. The Company plans to grow internally as well as through future acquisition(s). WEEKES FOREST PRODUCTS LOCATIONS Fargo, ND 800-548-2479 St. Paul, MN 800-328-2890 Green Bay, WI 800-236-6314 Milwaukee, WI 800-222-4698 Chicago, IL 800-398-8266 Grand Rapids, MI 800-442-8082 Tampa, FL-Logan Lumber Co. 800-365-5545 Corporate Culture. WEEKES is an informal, value-driven company where honesty, straight communication, and mutual respect are important. Teamwork, good product knowledge, strong work ethic and cost control are keys to the success of the company.

Mercedes-Benz of Henderson

Established in 1946 as well as being family owned and operated since 1946, the Fletcher Jones Company has grown into one of the largest and most respected automotive groups in the world. Our Preferred Owner Benefits include many amenities such as a complimentary Mercedes-Benz courtesy vehicle and a complimentary hand car wash.

NFW

NFW is a circularity platform for plastic-free performance materials. NFW follows three Ground Rules in everything we develop: start well, stay clean, end well. While nearly everything in the built world relies on some type of plastic that began as crude oil and that will become plastic pollution, we are establishing a new material reality. We believe all materials should begin and end as nutrients, ready for the next growth cycle—true circularity. Our multi-material platform serves a wide range of industries—from fashion and footwear to automotive and upholstery. NFW technology embeds seamlessly into existing supply chains, enabling the worlds most iconic brands to design and scale products with high-performance, plastic-free materials. NFW makes global brands more sustainable, empowering them to create without plastics. Alongside the boldest brands and visionary designers, we are pioneering a naturally circular, post-oil economy.

IMUNON

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.